
Sanofi
Founded Year
1973Stage
Corporate Minority - P2P | IPOMarket Cap
105.92BStock Price
86.31Revenue
$0000About Sanofi
Sanofi operates as a biopharmaceutical company focused on the healthcare industry. The company develops medicines and vaccines for various therapeutic areas including immunology, neurology, oncology, rare diseases, cardiovascular diseases, and diabetes, as well as vaccines. Sanofi was formerly known as Sanofi-Aventis. It was founded in 1973 and is based in Paris, France.
Loading...
Loading...
Research containing Sanofi
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Sanofi in 7 CB Insights research briefs, most recently on Jul 3, 2025.
Sanofi Patents
Sanofi has filed 3705 patents.
The 3 most popular patent topics include:
- drug delivery devices
- medical equipment
- dosage forms

Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
11/1/2018 | 4/8/2025 | Medical equipment, Drug delivery devices, Biodegradable plastics, Copolymers, Thermoplastics | Grant |
Application Date | 11/1/2018 |
|---|---|
Grant Date | 4/8/2025 |
Title | |
Related Topics | Medical equipment, Drug delivery devices, Biodegradable plastics, Copolymers, Thermoplastics |
Status | Grant |
Latest Sanofi News
Nov 5, 2025
Get 20% Off All Global Market Reports With Code ONLINE20 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors” — The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, November 5, 2025 / EINPresswire.com / -- "Get 20% Off All Global Market Reports With Code ONLINE20 – Stay Ahead Of Trade Shifts, Macroeconomic Trends, And Industry Disruptors What Is The Estimated Industry Size Of Seborrheic Dermatitis Market There has been a swift expansion in the seborrheic dermatitis market size in the past few years. From being valued at $2.76 billion in 2024, it is expected to rise to $3.05 billion in 2025, showcasing a compound annual growth rate (CAGR) of 10.7%. This significant growth during the historic period can be linked to factors such as enhanced diagnosis and increased awareness, a growing elder demographic, lifestyle influences, advancements in dermatology, and consumer inclination towards cosmetic solutions. In the upcoming years, the market size for seborrheic dermatitis is anticipated to experience a significant surge. It is projected to attain a value of $4.53 billion by 2029, registering a compound annual growth rate (CAGR) of 10.4%. This projected growth can be credited to factors such as increased preference for natural and herbal products, regulatory endorsement for emergent therapies, worldwide health readiness, and patient advocacy and support. During the forecast period, prominent trends are expected to be the inclusion of dermatology-specific technologies, studies on the impact of microbiome, personalized treatment methodologies, the rise of telemedicine and e-health solutions, and technological breakthroughs in skincare. Download a free sample of the seborrheic dermatitis market report: https://www.thebusinessresearchcompany.com/sample.aspx?id=13159&type=smp What Are The Major Factors Driving The Seborrheic Dermatitis Global Market Growth? The escalating occurrence of skin-related diseases is projected to stimulate the expansion of the seborrheic dermatitis market in the future. Terms like dermatological diseases encompass a wide range of medical issues that impact the skin, hair, nails, and mucous membranes. The relief from discomfort, enhancements in skin appearance, and prevention of complications such as infections or scarring brought about by dermatological disease treatments significantly uplifts the overall quality of life for those affected. As an illustration, data from the National Psoriasis Foundation, a non-profit organization based in the US, revealed in December 2022 that approximately 125 million people globally, roughly 2–3% of the world's population, were afflicted with psoriasis, a type of skin-related disease. Furthermore, more than 8 million Americans were identified as having psoriasis in 2022. Consequently, the spiralling incidence of dermatological diseases is anticipated to fuel the growth of the seborrheic dermatitis market. Who Are The Leading Companies In The Seborrheic Dermatitis Market? Major players in the Seborrheic Dermatitis include: • Pfizer Inc. • Johnson and Johnson • Merck and Co. Inc. • AbbVie Inc. • Bayer AG • Novartis AG • Sanofi S.A. • Bristol Myers Squibb Co • Abbott Laboratories • GlaxoSmithKline PLC What Are The Prominent Trends In The Seborrheic Dermatitis Market? Prominent enterprises in the seborrheic dermatitis market are putting their focus onto devising new and more potent medical treatments, such as roflumilast foam, in order to boost market sales. Roflumilast foam represents a breakthrough, enhanced daily topical solution for inflammation-based skin conditions, especially those located in hair-growing regions like the scalp, face and trunk. For example, in the month of April 2023, a medical dermatology company originating from the US, named Arcutis Biotherapeutics Inc., launched its new drug called roflumilast foam 0.3%. This is the first topical medication with a distinctive mode of action for treating seborrheic dermatitis to be approved by the US Food and Drug Administration (FDA), a government agency in the US, in over twenty years. Roflumilast foam, an under-investigation, once-a-day, topical formulation, is a highly potent and selective type 4 phosphodiesterase (PDE4) inhibitor, engineered to combat inflammatory dermatoses, mainly those occurring in hair-growing parts of the body. This medication is prescribed for treating seborrheic dermatitis in persons who are nine years old or older. What Are The Primary Segments Covered In The Global Seborrheic Dermatitis Market Report? The seborrheic dermatitismarket covered in this report is segmented – 1) By Treatment: Anti-Inflammatory, Antifungal, Corticosteroid Lotions, Sulfur Products, Other Treatments 2) By Diagnosis: Physical Examination, Biopsy, Other Diagnoses 3) By Dosage Form: Creams, Shampoos, Ointments, Gels, Other Dosage Forms 4) By Route Of Administration: Oral, Topical, Parenteral, Other Route Of Administrations 5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users Subsegments: 1) By Anti-Inflammatory: Topical Anti-Inflammatories, Systemic Anti-Inflammatories 2) By Antifungal: Topical Antifungal Creams, Oral Antifungal Medications 3) By Corticosteroid Lotions: Mild Corticosteroids, Moderate Corticosteroids, Potent Corticosteroids 4) By Sulfur Products: Sulfur Creams, Sulfur Shampoos 5) By Other Treatments: Keratolytics, Moisturizers, Herbal Remedies View the full seborrheic dermatitis market report: https://www.thebusinessresearchcompany.com/report/seborrheic-dermatitis-global-market-report Which Region Is Forecasted To Grow The Fastest In The Seborrheic Dermatitis Industry In 2024, North America dominated the seborrheic dermatitis market. The report on this market encompasses regions of Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East, and Africa. Browse Through More Reports Similar to the Global Seborrheic Dermatitis Market 2025, By The Business Research Company Airport Security Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/airport-security-global-market-report Airport Construction Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/airport-construction-global-market-report Airport Baggage Handling System Global Market Report 2025 https://www.thebusinessresearchcompany.com/report/airport-baggage-handling-system-global-market-report Speak With Our Expert: Saumya Sahay Americas +1 310-496-7795 Asia +44 7882 955267 & +91 8897263534 Europe +44 7882 955267 Email: saumyas@tbrc.info The Business Research Company - www.thebusinessresearchcompany.com Follow Us On: • LinkedIn: https://in.linkedin.com/company/the-business-research-company Oliver Guirdham The Business Research Company info@tbrc.info Visit us on social media: LinkedIn Facebook X Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Sanofi Frequently Asked Questions (FAQ)
When was Sanofi founded?
Sanofi was founded in 1973.
Where is Sanofi's headquarters?
Sanofi's headquarters is located at 46-48 Avenue de la Grande Armée, Paris.
What is Sanofi's latest funding round?
Sanofi's latest funding round is Corporate Minority - P2P.
Who are the investors of Sanofi?
Investors of Sanofi include Blackstone, Sanofi Ventures, Merck's EMEA Advance Biotech Grant and Nucleate Activator Program.
Who are Sanofi's competitors?
Competitors of Sanofi include Libbs, Medicines for Malaria Venture, Johnson & Johnson Innovative Medicine, Roivant, Viatris and 7 more.
Loading...
Compare Sanofi to Competitors

Novartis develops and offers a range of medicines aimed at treating serious diseases, providing support for patients and healthcare professionals, and conducting research to discover new therapies. The company also focuses on environmental sustainability and ethical practices in the pharmaceutical industry. It was founded in 1996 and is based in Basel, Switzerland.
Boehringer Ingelheim operates within the pharmaceutical and animal health sectors. The company conducts research and development of products for humans and animals. Boehringer Ingelheim serves the healthcare industry with an emphasis on pharmaceutical products. It was founded in 1885 and is based in Ingelheim am Rhein, Germany.
Teva México specializes in the pharmaceutical industry, focusing on the development and manufacturing of generic medications. The company offers a range of generic medicines designed to improve health outcomes for patients. Teva México primarily serves the healthcare sector by providing medication options. It is based in Ciudad de México, Mexico.
Sumitomo Pharma is a biopharmaceutical company focused on developing therapeutic and scientific breakthroughs. The company's main offerings include the development of novel cancer therapeutics and a robust pipeline of treatments aimed at addressing unmet clinical needs in oncology. Sumitomo Pharma was formerly known as Sumitomo Dainippon Pharma. It was founded in 1897 and is based in Osaka, Japan.

Taisho Pharmaceutical operates in the pharmaceutical industry. It provides medicinal drugs and over-the-counter medications. It was founded in 1912 and is based in Tokyo, Japan. In January 2024, Taisho Pharmaceutical was acquired by Otemon at a valuation of $4.88B.
Pfizer is a biopharmaceutical company involved in the discovery, development, and manufacturing of medications and vaccines aimed at improving health outcomes. The company serves the healthcare sector with its medical solutions. It is based in Jakarta, Indonesia.
Loading...






